PharmTech AI Pulse Check panelists explain why attribution, audit trails, and sign-off matter more than AI watermark detection for GxP quality teams.
Feature|Videos|May 19, 2026
Integrated Solutions for Complex Drug Development
Key Takeaways
- Understand the strategic evolution of Pace® Life Sciences as they celebrate 20 years of business.
- Learn how to make investment decisions around emerging technologies.
The evolution of Pace® Life Sciences from an analytical services firm to a full-service CDMO supporting the drug development lifecycle.
Sponsored by Pace® Life Sciences
As drug modalities grow increasingly complex—spanning biologics, cell and gene therapies, antibody drug conjugates, and combination formats—CDMOs are pivoting their tactics to support these modalities. Frank Tagliaferri, PhD, Chief Scientific Officer at Pace® Life Sciences, explains how Pace Analytical expanded into a broad-based CDMO serving clients across the drug development lifecycle, from late discovery through commercial products. Growth came through a combination of targeted acquisitions and organic investment, adding capabilities such as clinical trial manufacturing, regulatory consulting, and advanced analytical testing across multiple locations. This led to the creation of a platform model that focuses on anticipating client needs and accelerating access to data to support faster decision-making throughout the drug development process.
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Trending on Pharmaceutical Technology
1
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
2
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
3
PharmTech AI Pulse Check: Availability Bias Threatens AI Regulatory Reviews
4
What the Olanzapine Depot Approval Means for CMC Teams
5